Doxorubicin-induced death in tumour cells and cardiomyocytes: Is autophagy the key to improving future clinical outcomes?

Journal of Pharmacy and Pharmacology

Volumn 65, Issue 11, 2013, Pages 1577-1589

  Tacar, Oktay ^a   Dass, Crispin R ^b  

^a VICTORIA UNIVERSITY   (Australia)

^b CURTIN UNIVERSITY   (Australia)

Author keywords

autophagy; cancer; cardiotoxicity; cell death; doxorubicin

Indexed keywords

BECLIN 1; CASPASE; DOXORUBICIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; AUTOPHAGY; CANCER CELL CULTURE; CELL CYCLE ARREST; DRUG EFFICACY; DRUG MECHANISM; DRUG STRUCTURE; ENZYME ACTIVATION; HEART MUSCLE CELL; HUMAN; NONHUMAN; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; REVIEW; SENESCENCE; TUMOR CELL;

AUTOPHAGY; CANCER; CARDIOTOXICITY; CELL DEATH; DOXORUBICIN;

ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; AUTOPHAGY; DOXORUBICIN; HUMANS; MEMBRANE PROTEINS; MYOCYTES, CARDIAC; NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2;

EID: 84886090900     PISSN: 00223573     EISSN: 20427158     Source Type: Journal    
DOI: 10.1111/jphp.12144     Document Type: Review

References (87)

1. ACS-American Cancer Society. Facts and Figures. Philadelphia, PA: ACS, 2012.
2. Hahn WC, Weinberg RA,. Rules for making human tumor cells. N Engl J Med 2002; 347: 1593-1603.
3. Croce CM,. Oncogenes and cancer. N Engl J Med 2008; 358: 502-511.
4. Hanahan D, Weinberg RA,. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-674.
5. L'ecuyer T, et al. DNA damage is an early event in doxorubicin-induced cardiac myocyte death. Am J Physiol Heart Circ Physiol 2006; 291: H1273-1280.
6. Liu X, et al. Pifithrin-alpha protects against doxorubicin-induced apoptosis and acute cardiotoxicity in mice. Am J Physiol Heart Circ Physiol 2004; 286: H933-H939.
7. Liu J, et al. ERKs/p53 signal transduction pathway is involved in doxorubicin-induced apoptosis in H9c2 cells and cardiomyocytes. Am J Physiol Heart Circ Physiol 2008; 295: H1956-1965.
8. Chen MB, et al. Activation of AMP-activated protein kinase contributes to doxorubicin-induced cell death and apoptosis in cultured myocardial H9c2 cells. Cell Biochem Biophys 2011; 60: 311-322.
9. Yeh PY, et al. Phosphorylation of p53 on Thr55 by ERK2 is necessary for doxorubicin-induced p53 activation and cell death. Oncogene 2004; 23: 3580-3588.
10. Lorenzo E, et al. Doxorubicin induces apoptosis and CD95 gene expression in human primary endothelial cells through a p53-dependent mechanism. J Biol Chem 2002; 277: 10883-10892.
11. Panaretakis T, et al. Doxorubicin requires the sequential activation of caspase-2, protein kinase Cdelta, and c-Jun NH2-terminal kinase to induce apoptosis. Mol Biol Cell 2005; 16: 3821-3831.
12. Childs AC, et al. Doxorubicin treatment in vivo causes cytochrome C release and cardiomyocyte apoptosis, as well as increased mitochondrial efficiency, superoxide dismutase activity, and Bcl-2: Bax ratio. Cancer Res 2002; 62: 4592-4598.
13. Leung LK, Wang TT,. Differential effects of chemotherapeutic agents on the Bcl-2/Bax apoptosis pathway in human breast cancer cell line MCF-7. Breast Cancer Res Treat 1999; 55: 73-83.
14. Huigsloot M, et al. Differential regulation of doxorubicin-induced mitochondrial dysfunction and apoptosis by Bcl-2 in mammary adenocarcinoma (MTLn3) cells. J Biol Chem 2002; 277: 35869-35879.
15. Tu Y, et al. Upregulated expression of BCL-2 in multiple myeloma cells induced by exposure to doxorubicin, etoposide, and hydrogen peroxide. Blood 1996; 88: 1805-1812.
16. Ueno M, et al. Doxorubicin induces apoptosis by activation of caspase-3 in cultured cardiomyocytes in vitro and rat cardiac ventricles in vivo. J Pharmacol Sci 2006; 101: 151-158.
17. Gamen S, et al. Doxorubicin-induced apoptosis in human T-cell leukemia is mediated by caspase-3 activation in a Fas-independent way. FEBS Lett 1997; 417: 360-364.
18. Rebbaa A, et al. Caspase inhibition switches doxorubicin-induced apoptosis to senescence. Oncogene 2003; 22: 2805-2811.
19. Wang S, et al. Doxorubicin induces apoptosis in normal and tumor cells via distinctly different mechanisms. intermediacy of H(2)O(2)- and p53-dependent pathways. J Biol Chem 2004; 279: 25535-25543.
20. Jang YM, et al. Doxorubicin treatment in vivo activates caspase-12 mediated cardiac apoptosis in both male and female rats. FEBS Lett 2004; 577: 483-490.
21. Maestre N, et al. Cell surface-directed interaction of anthracyclines leads to cytotoxicity and nuclear factor kappaB activation but not apoptosis signaling. Cancer Res 2001; 61: 2558-2561.
22. Tietze MK, et al. IkappaBalpha gene therapy in tumor necrosis factor-alpha- and chemotherapy-mediated apoptosis of hepatocellular carcinomas. Cancer Gene Ther 2000; 7: 1315-1323.
23. Box VG,. The intercalation of DNA double helices with doxorubicin and nogalamycin. J Mol Graph Model 2007; 26: 14-19.
24. Carvalho C, et al. Doxorubicin: the good, the bad and the ugly effect. Curr Med Chem 2009; 16: 3267-3285.
25. Hilmer SN, et al. The hepatic pharmacokinetics of doxorubicin and liposomal doxorubicin. Drug Metab Dispos 2004; 32: 794-799.
26. Buchholz TA, et al. Global gene expression changes during neoadjuvant chemotherapy for human breast cancer. Cancer J 2002; 8: 461-468.
27. Lal S, et al. Pharmacogenetics of target genes across doxorubicin disposition pathway: a review. Curr Drug Metab 2010; 11: 115-128.
28. Tan ML, et al. Doxorubicin delivery systems based on chitosan for cancer therapy. J Pharm Pharmacol 2009; 61: 131-142.
29. Kiyomiya K, et al. Mechanism of specific nuclear transport of adriamycin: the mode of nuclear translocation of adriamycin-proteasome complex. Cancer Res 2001; 61: 2467-2471.
30. Minotti G, et al. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 2004; 56: 185-229.
31. Ashley N, Poulton J,. Mitochondrial DNA is a direct target of anti-cancer anthracycline drugs. Biochem Biophys Res Commun 2009; 378: 450-455.
32. Cardoso S, et al. Doxorubicin increases the susceptibility of brain mitochondria to Ca(2+)-induced permeability transition and oxidative damage. Free Radic Biol Med 2008; 45: 1395-1402.
33. Tacar O, et al. Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems. J Pharm Pharmacol 2012; 65: 157-170.
34. Kim YM, et al. Involvement of AMPK signaling cascade in capsaicin-induced apoptosis of HT-29 colon cancer cells. Ann N Y Acad Sci 2007; 1095: 496-503.
35. Kim YD, et al. Compound K induces apoptosis via CAMK-IV/AMPK pathways in HT-29 colon cancer cells. J Agric Food Chem 2009; 57: 10573-10578.
36. Guo D, et al. The AMPK agonist AICAR inhibits the growth of EGFRvIII-expressing glioblastomas by inhibiting lipogenesis. Proc Natl Acad Sci U S A 2009; 106: 12932-12937.
37. Jones RG, et al. AMP-activated protein kinase induces a p53-dependent metabolic checkpoint. Mol Cell 2005; 18: 283-293.
38. Pan W, et al. AMPK mediates curcumin-induced cell death in CaOV3 ovarian cancer cells. Oncol Rep 2008; 20: 1553-1559.
39. Cao C, et al. AMP-activated protein kinase contributes to UV- and H2O2-induced apoptosis in human skin keratinocytes. J Biol Chem 2008; 283: 28897-28908.
40. Okoshi R, et al. Activation of AMP-activated protein kinase induces p53-dependent apoptotic cell death in response to energetic stress. J Biol Chem 2008; 283: 3979-3987.
41. Kefas BA, et al. AMP-activated protein kinase can induce apoptosis of insulin-producing MIN6 cells through stimulation of c-Jun-N-terminal kinase. J Mol Endocrinol 2003; 30: 151-161.
42. Meisse D, et al. Sustained activation of AMP-activated protein kinase induces c-Jun N-terminal kinase activation and apoptosis in liver cells. FEBS Lett 2002; 526: 38-42.
43. Lee TK, et al. Doxorubicin-induced apoptosis and chemosensitivity in hepatoma cell lines. Cancer Chemother Pharmacol 2002; 49: 78-86.
44. Haupt S, et al. Apoptosis-the p53 network. J Cell Sci 2003; 116: 4077-4085.
45. Appella E, Anderson CW,. Post-translational modifications and activation of p53 by genotoxic stresses. Eur J Biochem 2001; 268: 2764-2772.
46. Levine AJ, Oren M,. The first 30 years of p53: growing ever more complex. Nat Rev Cancer 2009; 9: 749-758.
47. Vousden KH, Prives C,. Blinded by the light: the growing complexity of p53. Cell 2009; 137: 413-431.
48. Brown CJ, et al. Awakening guardian angels: drugging the p53 pathway. Nat Rev Cancer 2009; 9: 862-873.
49. Demidenko ZN, et al. Paradoxical suppression of cellular senescence by p53. Proc Natl Acad Sci U S A 2010; 107: 9660-9664.
50. Leontieva OV, et al. Weak p53 permits senescence during cell cycle arrest. Cell Cycle 2010; 9: 4323-4327.
51. Yang MY, et al. Induction of cellular senescence by doxorubicin is associated with upregulated miR-375 and induction of autophagy in K562 cells. PLoS ONE 2012; 7: e37205. doi: 10.1371/journal.pone.0037205.
52. Vigneron A, et al. Src inhibits adriamycin-induced senescence and G2 checkpoint arrest by blocking the induction of p21waf1. Cancer Res 2005; 65: 8927-8935.
53. Xue C, et al. p53 determines multidrug sensitivity of childhood neuroblastoma. Cancer Res 2007; 67: 10351-10360.
54. Levine B, et al. Bcl-2 family members: dual regulators of apoptosis and autophagy. Autophagy 2008; 4: 600-606.
55. Kang MH, Reynolds CP,. Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy. Clin Cancer Res 2009; 15: 1126-1132.
56. Yoshino T, et al. Bcl-2 expression as a predictive marker of hormone-refractory prostate cancer treated with taxane-based chemotherapy. Clin Cancer Res 2006; 12: 6116-6124.
57. Liu WH, Chang LS,. Fas/FasL-dependent and -independent activation of caspase-8 in doxorubicin-treated human breast cancer MCF-7 cells: ADAM10 down-regulation activates Fas/FasL signaling pathway. Int J Biochem Cell Biol 2011; 43: 1708-1719.
58. Yamaoka M, et al. Apoptosis in rat cardiac myocytes induced by Fas ligand: priming for Fas-mediated apoptosis with doxorubicin. J Mol Cell Cardiol 2000; 32: 881-889.
59. Pattingre S, et al. Bcl-2 antiapoptotic proteins inhibit Beclin 1-dependent autophagy. Cell 2005; 122: 927-939.
60. Eisenberg-Lerner A, et al. Life and death partners: apoptosis, autophagy and the cross-talk between them. Cell Death Differ 2009; 16: 966-975.
61. Maiuri MC, et al. Self-eating and self-killing: crosstalk between autophagy and apoptosis. Nat Rev Mol Cell Biol 2007; 8: 741-752.
62. Maiuri MC, et al. Crosstalk between apoptosis and autophagy within the Beclin 1 interactome. EMBO J 2010; 29: 515-516.
63. Wang J,. Beclin 1 bridges autophagy, apoptosis and differentiation. Autophagy 2008; 4: 947-948.
64. Shimizu S, et al. Role of Bcl-2 family proteins in a non-apoptotic programmed cell death dependent on autophagy genes. Nat Cell Biol 2004a; 6: 1221-1228.
65. Daniel F, et al. Partial Beclin 1 silencing aggravates doxorubicin- and Fas-induced apoptosis in HepG2 cells. World J Gastroenterol 2006; 12: 2895-2900.
66. Dalby KN, et al. Targeting the prodeath and prosurvival functions of autophagy as novel therapeutic strategies in cancer. Autophagy 2010; 6: 322-329.
67. Wirawan E, et al. Caspase-mediated cleavage of Beclin-1 inactivates Beclin-1-induced autophagy and enhances apoptosis by promoting the release of proapoptotic factors from mitochondria. Cell Death Dis 2010; 1. doi: 10.1038/cddis.2009.16.
68. An T, et al. Neuregulin-1 attenuates doxorubicin-induced autophagy in neonatal rat cardiomyocytes. J Cardiovasc Pharmacol 2013; 62: 130-137.
69. Fulda S, Debatin KM,. Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene 2006; 25: 4798-4811.
70. Hyman BT, Yuan J,. Apoptotic and non-apoptotic roles of caspases in neuronal physiology and pathophysiology. Nat Rev Neurosci 2012; 13: 395-406.
71. Youn HJ, et al. Induction of caspase-independent apoptosis in H9c2 cardiomyocytes by adriamycin treatment. Mol Cell Biochem 2005; 270: 13-19.
72. Fernando P, Megeney LA,. Is caspase-dependent apoptosis only cell differentiation taken to the extreme? FASEB J 2007; 21: 8-17.
73. Bouchier-Hayes L,. The role of caspase-2 in stress-induced apoptosis. J Cell Mol Med 2010; 14: 1212-1224.
74. Narula J, et al. Apoptosis in heart failure: release of cytochrome c from mitochondria and activation of caspase-3 in human cardiomyopathy. Proc Natl Acad Sci U S A 1999; 96: 8144-8149.
75. Yang XH, et al. Reconstitution of caspase 3 sensitizes MCF-7 breast cancer cells to doxorubicin- and etoposide-induced apoptosis. Cancer Res 2001; 61: 348-354.
76. Ho LH, et al. A tumor suppressor function for caspase-2. Proc Natl Acad Sci U S A 2009; 106: 5336-5341.
77. Dass CR,. Use of caspase-2 as a biomarker for osteosarcoma. J Mol Biomarkers Diag 2011; 2: 29.
78. Tinel A, Tschopp J,. The PIDDosome, a protein complex implicated in activation of caspase-2 in response to genotoxic stress. Science 2004; 304: 843-846.
79. Kim SH, Dass CR,. Induction of caspase-2 activation by a DNA enzyme evokes tumor cell apoptosis. DNA Cell Biol 2012; 31: 1-7.
80. Dass CR, et al. A c-jun DNAzyme which is a potent inducer of caspase-2 activation. Oligonucleotides 2010; 20: 137-146.
81. Panaretakis T, et al. Activation of Bak, Bax, and BH3-only proteins in the apoptotic response to doxorubicin. J Biol Chem 2002; 277: 44317-44326.
82. Zhang YW, et al. Cardiomyocyte death in doxorubicin-induced cardiotoxicity. Arch Immunol Ther Exp (Warsz) 2009; 57: 435-445.
83. Neilan TG, et al. Disruption of nitric oxide synthase 3 protects against the cardiac injury, dysfunction, and mortality induced by doxorubicin. Circulation 2007; 116: 506-514.
84. Shizukuda Y, et al. Targeted disruption of p53 attenuates doxorubicin-induced cardiac toxicity in mice. Mol Cell Biochem 2007; 273: 25-32.
85. Shimizu S, et al. Role of Bcl-2 family proteins in a non-apoptotic programmed cell death dependent on autophagy genes. Nat Cell Biol 2004b; 6: 1221-1228.
86. Gustafsson AB, Gottlieb RA,. Autophagy in ischemic heart disease. Circ Res 2009; 104: 150-158.
87. Hoyer-Hansen M, et al. Control of macroautophagy by calcium, calmodulin-dependent kinase kinase-beta, and Bcl-2. Mol Cell 2007; 25: 193-205.